ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Mycovia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis
June 11, 2021Mycovia Pharmaceuticals, Inc. today announced it has submitted its New Drug Application (NDA) for oteseconazole, an oral antifungal product for the treatment of recurrent vulvovaginal candidiasis (RVVC). -
Mycovia and Jaingsu to commercialise VT-1161 for RVVC
June 19, 2019Mycovia Pharmaceuticals has partnered with Jiangsu Hengrui Medicine to develop and commercialise its investigational drug VT-1161 (otesaconazole) in China.
Pharma Sources Insight January 2025
